vs
Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and MFA FINANCIAL, INC. (MFA). Click either name above to swap in a different company.
4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $55.5M, roughly 1.5× MFA FINANCIAL, INC.). On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 9.2%). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 7.7%).
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
MFA Financial, Inc. is a U.S.-headquartered real estate investment trust (REIT) specializing in investing in and managing residential and commercial mortgage-backed securities, mortgage loans, and other real estate-related financial assets. It caters primarily to institutional and individual investors across the U.S., focusing on delivering stable risk-adjusted returns via rigorous asset screening and risk management frameworks.
FDMT vs MFA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $85.1M | $55.5M |
| Net Profit | $19.4M | — |
| Gross Margin | — | — |
| Operating Margin | 17.3% | 97.9% |
| Net Margin | 22.8% | — |
| Revenue YoY | 8508900.0% | 9.2% |
| Net Profit YoY | 139.1% | — |
| EPS (diluted) | $0.43 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $85.1M | $55.5M | ||
| Q3 25 | $90.0K | $56.8M | ||
| Q2 25 | $15.0K | $61.3M | ||
| Q1 25 | $14.0K | $57.5M | ||
| Q4 24 | $1.0K | $50.8M | ||
| Q3 24 | $3.0K | $50.6M | ||
| Q2 24 | $5.0K | $53.5M | ||
| Q1 24 | $28.0K | $47.8M |
| Q4 25 | $19.4M | — | ||
| Q3 25 | $-56.9M | $48.1M | ||
| Q2 25 | $-54.7M | $33.2M | ||
| Q1 25 | $-48.0M | $41.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-43.8M | $48.2M | ||
| Q2 24 | $-35.0M | $41.9M | ||
| Q1 24 | $-32.4M | $23.2M |
| Q4 25 | 17.3% | 97.9% | ||
| Q3 25 | -67983.3% | 84.5% | ||
| Q2 25 | -396373.3% | 54.5% | ||
| Q1 25 | -383007.1% | 70.0% | ||
| Q4 24 | — | 6.8% | ||
| Q3 24 | -1704400.0% | 98.2% | ||
| Q2 24 | -849120.0% | 79.1% | ||
| Q1 24 | -136200.0% | 50.7% |
| Q4 25 | 22.8% | — | ||
| Q3 25 | -63195.6% | 84.7% | ||
| Q2 25 | -364386.7% | 54.2% | ||
| Q1 25 | -342657.1% | 71.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | -1461433.3% | 95.2% | ||
| Q2 24 | -699060.0% | 78.4% | ||
| Q1 24 | -115717.9% | 48.5% |
| Q4 25 | $0.43 | $0.43 | ||
| Q3 25 | $-1.01 | $0.35 | ||
| Q2 25 | $-0.98 | $0.21 | ||
| Q1 25 | $-0.86 | $0.31 | ||
| Q4 24 | — | $-0.01 | ||
| Q3 24 | $-0.79 | $0.37 | ||
| Q2 24 | $-0.63 | $0.32 | ||
| Q1 24 | $-0.66 | $0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $402.7M | $213.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $505.7M | $1.8B |
| Total Assets | $566.7M | $13.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $402.7M | $213.2M | ||
| Q3 25 | $305.1M | $305.2M | ||
| Q2 25 | $293.2M | $275.7M | ||
| Q1 25 | $321.4M | $253.7M | ||
| Q4 24 | $424.9M | $338.9M | ||
| Q3 24 | $501.9M | $305.6M | ||
| Q2 24 | $541.9M | $289.4M | ||
| Q1 24 | $525.9M | $306.3M |
| Q4 25 | $505.7M | $1.8B | ||
| Q3 25 | $369.0M | $1.8B | ||
| Q2 25 | $420.9M | $1.8B | ||
| Q1 25 | $469.7M | $1.8B | ||
| Q4 24 | $510.6M | $1.8B | ||
| Q3 24 | $552.9M | $1.9B | ||
| Q2 24 | $588.3M | $1.9B | ||
| Q1 24 | $600.6M | $1.9B |
| Q4 25 | $566.7M | $13.0B | ||
| Q3 25 | $424.0M | $12.1B | ||
| Q2 25 | $473.6M | $11.7B | ||
| Q1 25 | $515.7M | $11.5B | ||
| Q4 24 | $560.4M | $11.4B | ||
| Q3 24 | $604.0M | $11.2B | ||
| Q2 24 | $620.1M | $11.1B | ||
| Q1 24 | $629.9M | $10.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.6M | $76.2M |
| Free Cash FlowOCF − Capex | $28.5M | — |
| FCF MarginFCF / Revenue | 33.5% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | 1.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-109.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.6M | $76.2M | ||
| Q3 25 | $-46.5M | $14.7M | ||
| Q2 25 | $-43.4M | $38.5M | ||
| Q1 25 | $-47.8M | $-14.6M | ||
| Q4 24 | $-134.6M | $200.1M | ||
| Q3 24 | $-29.4M | $-11.3M | ||
| Q2 24 | $-30.2M | $46.5M | ||
| Q1 24 | $-29.1M | $53.5M |
| Q4 25 | $28.5M | — | ||
| Q3 25 | $-46.6M | — | ||
| Q2 25 | $-43.4M | — | ||
| Q1 25 | $-48.4M | — | ||
| Q4 24 | $-138.4M | — | ||
| Q3 24 | $-31.2M | — | ||
| Q2 24 | $-30.6M | — | ||
| Q1 24 | $-29.8M | — |
| Q4 25 | 33.5% | — | ||
| Q3 25 | -51765.6% | — | ||
| Q2 25 | -289620.0% | — | ||
| Q1 25 | -345635.7% | — | ||
| Q4 24 | -13837100.0% | — | ||
| Q3 24 | -1038966.7% | — | ||
| Q2 24 | -611840.0% | — | ||
| Q1 24 | -106421.4% | — |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 101.1% | — | ||
| Q2 25 | 440.0% | — | ||
| Q1 25 | 4507.1% | — | ||
| Q4 24 | 378600.0% | — | ||
| Q3 24 | 59266.7% | — | ||
| Q2 24 | 6980.0% | — | ||
| Q1 24 | 2535.7% | — |
| Q4 25 | 1.47× | — | ||
| Q3 25 | — | 0.31× | ||
| Q2 25 | — | 1.16× | ||
| Q1 25 | — | -0.35× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -0.23× | ||
| Q2 24 | — | 1.11× | ||
| Q1 24 | — | 2.30× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
